Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs.

摘要: In 1998, the Food and Drug Administration (FDA) approved licensure of tobramycin solution for inhalation (TOBI). Although a number additional antibiotics, including other aminoglycosides, beta-lactams, antibiotics in polymyxin class, vancomycin, have been administered as aerosols many years, none are by FDA administration inhalation. TOBI was maintenance therapy patients 6 years or older with cystic fibrosis (CF) who between 25% 75% predicted forced expiratory volume 1 second (FEV(1)), colonized Pseudomonas aeruginosa, able to comply prescribed medical regimen. not acute pulmonary exacerbations CF nor it use without CF. Currently, no The purpose this statement is briefly summarize data that supported approval provide recommendations its safe use. pharmacokinetics inhaled aminoglycosides problems associated aerosolized antibiotic treatment, environmental contamination, selection resistant microbes, airway exposure excipients intravenous formulations, will be discussed.